Advanced AMD Monitoring Using OCT-A for Non-Exudative MNV

Overview

OCT-angiography (OCT-A) enables precise, long-term monitoring of non-exudative macular neovascularization (NE-MNV) in age-related macular degeneration (AMD). This case highlights stable NE-MNV over years with no exudation, emphasizing the importance of frequent imaging and home monitoring to detect progression.

Background

Non-exudative macular neovascularization (NE-MNV) in AMD refers to treatment-naïve type 1 neovascular lesions without associated fluid or hemorrhage. OCT-A has improved detection and understanding of NE-MNV, which carries a significantly increased risk of progression to exudative AMD. Current management involves close observation and monitoring, as anti-VEGF therapy is reserved for cases with exudation. Understanding lesion stability and progression risk is critical for optimizing follow-up intervals and patient care.

Data Highlights

A 75-year-old female with intermediate AMD and NE-MNV was monitored over 4 years using OCT and OCT-A. Visual acuity remained stable at 20/20 OD and 20/30 OS. OCT-A showed a slightly enlarged but stable non-exudative CNV lesion OS with no intraretinal or subretinal fluid. The 2-year cumulative risk of exudation in eyes with NE-MNV is 13.6 times greater than in eyes without detectable lesions, underscoring the need for frequent monitoring.

Key Findings

• OCT-A allows detailed visualization and monitoring of NE-MNV lesions in AMD patients.
• NE-MNV lesions can remain stable for years without progression to exudation.
• The presence of NE-MNV increases the risk of future exudation by over 13-fold within 2 years.
• Home monitoring devices like ForeseeHome complement clinical imaging for early detection of vision changes.
• Anti-VEGF treatment is reserved for cases with evidence of exudation; observation is standard for stable NE-MNV.
• Follow-up intervals should be shortened upon new NE-MNV detection, typically every 4 to 6 months for chronic lesions.

Clinical Implications

Clinicians should utilize OCT-A to detect and monitor NE-MNV in AMD patients, recognizing the increased risk of progression to exudation. Regular follow-up every 4 to 6 months is appropriate for stable lesions, with more frequent visits if new lesions are detected. Incorporating home monitoring technologies can aid in early identification of symptomatic changes, facilitating timely intervention.

Conclusion

OCT-A is a valuable tool for the long-term management of NE-MNV in AMD, enabling detection of lesion stability and risk stratification. Careful monitoring and patient compliance with home vision testing and supplements support optimal outcomes.

References

1. Dierker DD -- Advanced AMD Monitoring Using OCT-A